Clary Clish is the director of the Metabolite Profiling Platform at the Broad Institute of MIT and Harvard. Clish, who joined the Broad Institute in 2008, is an expert in profiling metabolites, the unique chemical fingerprints that result from both normal and pathological cellular processes.
Under the supervision of Dr. David Peyton (Portland State University) and Dr. Eric Barklis (Vollum Institute, Oregon Health & Science University), his doctoral research focused on the elucidation of the three-dimensional structures of retroviral protein structures using multidimensional nuclear magnetic resonance spectroscopy and computational methods.
Clish was a postdoctoral fellow and instructor in the laboratory of Dr. Charles Serhan at the Center for Experimental Therapeutics and Reperfusion Injury at Brigham & Women’s Hospital. In the Serhan laboratory, his work focused on understanding the roles of lipid mediators in acute inflammation and its resolution. Along with Serhan, Clish discovered and characterized a new class of anti-inflammatory lipid mediators that have been since been named “resolvins” and are currently being developed as potential therapeutics.
Clish worked for Beyond Genomics Inc., where he led the company’s comparative metabolite profiling and biomarker discovery programs in cancer, cardiovascular disease, and metabolic disease.
He was vice president of discovery research at Ore Pharmaceuticals Inc. (formerly Gene Logic Inc.) where he led programs in indications discovery for drug candidate molecules. Additionally, Clish oversaw the company’s metabolite profiling, in silico biology, and genomic pharmacology platform technologies.
Clish received his B.Sc. from McGill University in chemistry and biological sciences and his Ph.D. from Portland State University.